Endobronchial Valve Market Growth at 5.75% CAGR to Reach USD 310.27 Mn by 2032

Key Highlights

• Endobronchial Valve Market was valued at USD 209.78 Mn in 2025.
• Revenue is expected to reach USD 310.27 Mn by 2032.
• The market is projected to grow at a 5.75% CAGR during 2026–2032.
• Duckbill-shaped Endobronchial Valves showed the highest product demand in 2025.
• Hospitals represented the largest and most demanded end-user segment in 2025.
• North America led the global market in 2025.
• Around 65 million people worldwide suffer from COPD.
• Pulmonx reported worldwide 2025 revenue of approximately USD 90 Mn.
• Olympus released SeleCT Screening, an AI-powered software for identifying Spiration Valve System candidates, in June 2025.

Why This Matters Now

COPD and emphysema care is moving beyond drug management toward minimally invasive device intervention. Hospitals and pulmonary programs that cannot identify suitable patients and deliver bronchoscopic lung volume reduction risk falling behind in severe respiratory care.

Endobronchial Valve Market move from USD 209.78 Mn in 2025 to USD 310.27 Mn by 2032 signals steady adoption, not speculative demand. The next phase depends on patient screening, reimbursement support, trained pulmonologists and real-world evidence.

Market Overview

An endobronchial valve is a medical device implanted in the airway of the pulmonary system. It is a one-way valve designed to let air exit a targeted lung segment while preventing inspired air from re-entering.

This mechanism supports deflation of the emphysematous lung portion and enables lung volume reduction. The valves are typically implanted using a flexible delivery catheter advanced through a bronchoscope, making the procedure minimally invasive.

Demand is driven by awareness of bronchoscopic lung volume reduction for lung-related diseases. MMR identifies COPD and emphysema as core demand areas, with tobacco smoking and geriatric vulnerability increasing the patient pool.

Request Sample Report at : https://www.maximizemarketresearch.com/request-sample/88552/

Key Trends Driving Growth

COPD burden is the main growth driver. Around 65 million people worldwide suffer from COPD, and emphysema is the most common type. This creates a clear clinical base for endobronchial valve evaluation.

The market is also supported by limited substitutes. MMR states that no particular substitute is available for endobronchial valves in minimally invasive lung volume reduction. That strengthens device relevance for eligible severe emphysema patients.

Patient identification is becoming more data-driven. Pulmonx’s partnership with JAEGER Medical and Olympus’ AI-powered SeleCT Screening show the market moving toward better qualification before treatment. Better screening can reduce procedure delays and improve outcome selection.

Cost remains a barrier. High surgical-procedure cost and post-operative adhesion issues can slow broader adoption. That puts pressure on manufacturers to prove clinical value and support payer confidence.

Segment Insights

• Dominant Product Segment: Duckbill-shaped Endobronchial Valves. These valves showed the highest demand in 2025 because of effective one-way airflow control, strong clinical outcomes in lung volume reduction procedures and ease of bronchoscopic placement.
• Fastest-Growing Segment: Not disclosed. The visible MMR page does not identify a formally fastest-growing product, end-user, indication, material or placement-technique segment.
• Secondary Product Segment: Umbrella-shaped Endobronchial Valves. These maintain significant demand in specific anatomical conditions where design supports anchorage and sealing.
• Dominant End User: Hospitals. Hospitals represented the largest end-user segment in 2025 because they have bronchoscopy infrastructure, skilled pulmonologists and post-procedure monitoring facilities.
• Emerging End-User Signal: Ambulatory Surgery Centers. ASCs are gradually expanding their role because minimally invasive techniques can support shorter recovery times and cost-effective procedural settings.
• Covered Indications: Emphysema, Pneumothorax, COPD and Other Respiratory Conditions. Emphysema and COPD are the clearest demand signals in the visible summary.
• Covered Materials and Techniques: Silicone, Metal Alloy such as Nitinol, Polymer-based and Composite Materials; Bronchoscopic Placement and Surgical Placement. Bronchoscopic placement is central to the minimally invasive value proposition.

Regional Growth Story

North America leads the global Endobronchial Valve Market in 2025. The region benefits from advanced healthcare infrastructure, high awareness of minimally invasive respiratory treatments and strong reimbursement frameworks.

The region also benefits from early adoption of bronchoscopic lung volume reduction and the presence of leading medical-device manufacturers. The United States is included in the regional scope, but visible country-level revenue is not disclosed.

Europe follows closely. Growth is supported by clinical guidelines and an increasing geriatric population. Germany and the UK are included in the report scope, but visible country-specific values are unavailable.

Asia Pacific shows steady growth due to rising healthcare investments and expanding pulmonology services, particularly in emerging economies. China, India, Japan and South Korea are included in the scope, but the page does not disclose country-level revenues.

Competitive Landscape

The market includes pulmonary device specialists, respiratory-device companies and large medical-technology manufacturers. Key players include Pulmonx Corporation, Olympus Corporation, Boston Scientific, Medtronic, Teleflex, Cook Medical, Terumo, Ambu, Novatech, Broncus Medical, Spiration, Vyaire Medical, Merit Medical Systems, Micro-Tech Nanjing, Smiths Medical, ENDOFLEX, Xact Robotics, Vapotherm, Johnson & Johnson, Getinge and Nihon Kohden.

Pulmonx is positioned around Zephyr Valve procedure adoption. Olympus is positioned around the Spiration Valve System and supporting software, registry evidence and patient education. These strategies show that the market is moving beyond the valve itself toward treatment pathways.

Competition is increasingly shaped by screening tools, clinical evidence and physician workflow. Manufacturers that can help providers identify eligible patients faster will gain stronger procedural adoption.

Request Sample Report at : https://www.maximizemarketresearch.com/request-sample/88552/

Recent Developments

• Pulmonx released full-year 2025 financial results on 04 March 2026, reporting worldwide revenue of approximately USD 90 Mn. The result signals sustained Zephyr Valve procedure volumes and confirms global adoption across more than 25 countries.
• Pulmonx appointed Derrick Sung, Ph.D., as Chief Operating Officer and Chief Financial Officer on 20 February 2026. The leadership move targets commercial scaling and operational efficiency as COPD treatment pathways expand.
• Olympus updated the STRIVE Post-Market Registry Study on 26 November 2025. The 36-month safety and effectiveness study strengthens real-world evidence for the Spiration Valve System.
• Olympus partnered with the COPD Foundation on 11 November 2025. The collaboration supports patient education and may improve awareness of bronchoscopic lung volume reduction therapies.
• Pulmonx partnered with JAEGER Medical GmbH on 27 August 2025. The integration with SentrySuite improves patient-screening data qualification for Zephyr Valve eligibility.
• Olympus released SeleCT Screening on 12 June 2025. The AI-powered software uses automated chest CT review to identify candidates for the Spiration Valve System faster.

Strategic Implications

For hospitals, endobronchial valves require more than device procurement. Programs need bronchoscopy infrastructure, skilled pulmonologists, post-procedure monitoring and patient-selection workflows.

For payers, strong reimbursement frameworks in North America support adoption, but cost remains a pressure point. Clinical evidence from registries can help justify coverage and procedural pathways.

For manufacturers, AI screening and diagnostic integration are becoming competitive tools. Devices that come with better patient-identification systems can shorten evaluation timelines.

For patients, the value is minimally invasive lung volume reduction where no direct substitute exists. Better screening should improve access for eligible COPD and emphysema patients.

Future Outlook

The Endobronchial Valve Market is positioned for steady expansion as COPD burden, emphysema prevalence, geriatric respiratory disease, bronchoscopic lung volume reduction awareness and AI-assisted screening increase adoption. North America leads through reimbursement, infrastructure and early procedure adoption, while Asia Pacific gains from healthcare investment and expanding pulmonology services.

Future leaders will combine proven valves, AI-enabled screening, registry evidence and hospital workflow support, while laggards will lose share where providers demand faster patient selection and clearer treatment value.

Related Reports

global N95 Mask Market: https://www.maximizemarketresearch.com/market-report/global-n95-mask-market/105931/

Acne Treatment Market: https://www.maximizemarketresearch.com/market-report/acne-treatment-market/214013/

Global Body Composition Analyzers Market: https://www.maximizemarketresearch.com/market-report/global-body-composition-analyzers-market/31027/

Analyst Perspective

“According to Komal Patil, Research Analyst at Maximize Market Research, ‘The Endobronchial Valve Market is projected to grow from USD 209.78 Mn in 2025 to nearly USD 310.27 Mn by 2032 at a 5.75% CAGR, supported by COPD burden, emphysema treatment demand, bronchoscopic lung volume reduction and AI-enabled patient screening. Duckbill-shaped valves lead the visible product structure, while hospitals lead end-user demand. Companies that integrate device performance with screening, education and clinical evidence will be better positioned.’”

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.

2nd Floor, Navale IT Park Phase 3

Pune Banglore Highway, Narhe

Pune, Maharashtra 411041, India

+91 9607365656

sales@maximizemarketresearch.com